How should I evaluate a 59-year-old male with a 15-year history of recurrent fluid‑filled bullae, vasculitic skin ulcers, positive antihistone antibodies, and red‑cell sickling?

Evaluation of a 59-Year-Old Male with Bullae, Vasculitic Ulcers, Antihistone Antibodies, and RBC Sickling

This patient requires immediate evaluation for drug-induced lupus with vasculitis in the context of sickle cell disease, with urgent skin biopsy including direct immunofluorescence (DIF) to differentiate between autoimmune bullous disease and vasculitic bullae.

Diagnostic Approach

Initial Blood Work (Before Biopsy)

Obtain the following laboratory tests immediately 1:

• Complete blood count with differential - to assess for leukemia, anemia severity, and confirm sickle cell disease status
• Hemoglobin electrophoresis - if sickle cell disease not previously confirmed 2
• Reticulocyte count, LDH, bilirubin, AST - elevated in sickle cell disease with acute complications 2
• Coagulation studies - to exclude biopsy contraindications 1
• Fasting blood glucose - hyperglycemia predisposes to invasive fungal infection 1
• HIV antibody and syphilis serology - to rule out infectious causes of ulceration 1
• Serum autoantibodies: Anti-Dsg1, Dsg3, BP180, BP230 by ELISA - crucial before biopsy if bullous pemphigoid suspected 1, 3
• ANA panel and anti-dsDNA - antihistone antibodies suggest drug-induced lupus or SLE with vasculitis 4, 5

Critical Diagnostic Consideration

The combination of antihistone antibodies positive + vasculitic ulcers strongly suggests either:

1. Drug-induced lupus with vasculitis (most likely given antihistone antibodies 5)
2. Systemic lupus erythematosus with vasculitis
3. Rheumatoid vasculitis (though less likely without joint symptoms 5)

The presence of sickle cell disease adds complexity - systemic necrotizing vasculitis can occur in SCD patients, though rarely reported 6. The highest antihistone reactivity and most heterogeneous response patterns occur in rheumatoid arthritis with vasculitis 5.

Skin Biopsy Protocol

Perform multiple biopsies if lesions have different morphological characteristics 1:

1. For bullae: Take biopsy from perilesional skin (not the blister itself) and send in Michel's medium or snap-frozen for DIF 3

   • DIF will show IgG linear deposition at basement membrane zone in bullous pemphigoid 3
   • Pauci-immune pattern (negative DIF) suggests vasculitis, not bullous pemphigoid 7

2. For vasculitic ulcers: Take deep biopsy including subcutaneous tissue

   • Send for routine H&E staining
   • Must include DIF - this is non-negotiable to differentiate IgA vasculitis from ANCA-associated vasculitis 7
   • Leukocytoclastic vasculitis without immune deposits (pauci-immune) suggests ANCA-associated vasculitis 7

3. Additional testing on biopsy specimens:

   • If hematopoietic/lymphoid neoplasm suspected: immunohistochemistry, T-cell receptor immunophenotyping 1

Common Pitfalls to Avoid

Do NOT assume IgA vasculitis based on leukocytoclastic pattern alone - failure to perform DIF and ANCA testing causes diagnostic delay and irreversible organ damage 7. A 47-year-old case initially misdiagnosed as IgA vasculitis (without DIF) returned with necrotizing ulcers and pulmonary hemorrhage from granulomatosis with polyangiitis 7.

Do NOT delay biopsy - ulcers persisting >2 weeks or not responding to 1-2 weeks of treatment require biopsy 1.

Systemic Evaluation

Given the 15-year history and multiple organ systems involved:

• Pulmonary assessment: Check for pulmonary hypertension (30% prevalence in sickle cell disease, 50% 2-year mortality if present) 8
• Renal function: Urinalysis for hematuria/proteinuria - nephropathy common in both SCD and lupus
• Cardiovascular: Echocardiography if systemic steroids or immunosuppression planned 9
• Screen for underlying malignancy appropriate to age and clinical history 9

Management Considerations Based on Likely Diagnoses

If Bullous Pemphigoid Confirmed:

• Superpotent topical corticosteroids (clobetasol 0.05%) as first-line for localized disease 10, 9
• Oral prednisone 0.5-1 mg/kg/day for extensive disease, taper over ≥4 weeks 10, 9
• Consider steroid-sparing agents (rituximab, IVIg) given sickle cell disease comorbidity 10

If Vasculitis Confirmed:

• Immunosuppression with corticosteroids ± cyclophosphamide or rituximab depending on severity
• Avoid further transfusion unless life-threatening anemia in sickle cell patients 11

Sickle Cell Disease Management:

• Continue hydroxyurea as first-line disease-modifying therapy 12, 13
• Consider adjunctive agents (L-glutamine, crizanlizumab, voxelotor) 12, 13

The 15-year chronicity suggests this is NOT acute sickle cell crisis but rather a chronic autoimmune/vasculitic process superimposed on underlying hemoglobinopathy.